Show simple item record

dc.contributor.advisorParra Serrano, Gustavo
dc.contributor.advisorCamacho López, Paul Anthony
dc.contributor.advisorVesga Angarita, Boris Eduardo
dc.contributor.authorDelgado Muñoz, Erika Noelia
dc.coverage.spatialFloridablanca (Santander, Colombia)spa
dc.date.accessioned2020-07-19T18:22:08Z
dc.date.available2020-07-19T18:22:08Z
dc.date.issued2020-02
dc.identifier.urihttp://hdl.handle.net/20.500.12749/6980
dc.description.abstractIntroducción: La Hipercolesterolemia Familiar Heterocigota (HFHe) es una enfermedad genética caracterizada por tener niveles plasmáticos de c-LDL elevados, generalmente mayores de 190 mg/dL y una alta morbimortalidad cardiovascular. A pesar de su alto impacto social y económico, continúa siendo una patología infradiagnosticada e infratratada. Diseño: Estudio observacional, analítico de corte transversal, de datos secundarios anonimizados Métodos: Los criterios de inclusión fueron, pacientes adultos mayores o iguales a 18 años con enfermedad aterosclerótica coronaria (Pacientes con cardiopatía isquémica definida por infarto de miocardio, angina de pecho, cirugía o cualquier otro procedimiento de revascularización coronaria) y/o cerebral establecida (pacientes con enfermedad cerebrovascular o accidente isquémico transitorio); en tanto que el criterio de exclusión fue no tener un perfil lipídico valorable. Resultados: Se realizó una revisión del registro de la base de datos de 470 pacientes. La edad promedio fue de 64.83 años y la mayoría fueron hombres (63.83%). La HTA fue el factor de riesgo más prevalente (72.77%) seguido por la dislipidemia o estar en tratamiento farmacológico hipolipemiante (57.45%) y el tabaquismo (40.42%). El Infarto agudo de miocardio (IAM) fue la forma de presentación más frecuente de los eventos cardiovasculares (44.04%), seguido de la angina de pecho (45.53%) y Enfermedad cerebrovascular (ECV) isquémica (9.36%) principalmente. 33.19% de los casos tuvo afectación de un único vaso en la arteriografía coronaria, mientras que el 20.64% y 23.40% de los casos tuvo afectación de 2 y 3 o más vasos, respectivamente. El valor promedio de colesterol LDL (c-LDL) fue de 112.60 mg/dl y solo el 11.91% de los pacientes tenían valores en la meta establecida para esta condición. El 43.96% de la población recibía algún tipo de estatina, pero solo el 7.60% en dosis máxima. La Atorvastatina fue la estatina más prescrita (86.85%) posterior al evento cardiovascular. El 7.45% de los sujetos fueron clasificados como casos posibles de HFHe y el 0.43% como casos probables. No se encontraron casos definitivos al no disponerse de análisis genético. Se estableció que el 7.8% de la población estudiada tiene HFHe posible/probable. Se determinó dependencia estadísticamente significativa (p<0.0001), entre la HFHe y la edad de presentación de eventos cardiovasculares más tempranos (55.83 años vs 65.60 años), así como con el sexo femenino (p 0.021). En cuanto a los factores de riesgo, solo se observó dependencia entre tener historia de HF en primer grado de consanguinidad e historia familiar de IAM prematuro con la prevalencia de HFHe posible/probable (p<0.0001). Los pacientes con HFHe posible/probable tuvieron niveles de CT (colesterol total), TAG (triglicéridos) y c-LDL más elevados (p<0.0001). Se encontró dependencia entre el valor de creatinina (0.82 mg/dl) y la prevalencia de HFHe (p 0.005). La mayoría de los pacientes con HFHe posible/probable realizan otro tipo de ejercicio aeróbico diferente a la caminata (p 0.016). El tratamiento combinado fue prescrito 4 veces más (10.81% vs 2.54%) después del evento cardiovascular en el grupo de HF posible/probable (p 0.02). Mientras que la implantación de Stent coronario fue la estrategia de revascularización más usada en general (63.19%), la cirugía de revascularización miocárdica fue usada 2 veces más en la población con HFHe posible/probable (p 0.042). Conclusiones: La HFHe es una enfermedad infradiagnosticada entre los pacientes que presentan enfermedad aterosclerótica establecida y acorta la edad de presentación de eventos cardiovasculares con respecto a la población general. Los resultados consolidan la importancia de crear una cohorte de pacientes con HFHe que padezcan algún evento cardiovascular con el fin de optimizar las medidas de tratamiento para poder reducir el impacto de la enfermedad cardiovascular y los costos relacionados con la atención y el tratamiento.spa
dc.description.sponsorshipFOSCALspa
dc.description.sponsorshipInstituto del Corazón de Bucaramangaspa
dc.description.tableofcontentsLISTA DE TABLAS ............................................................................................. 9 LISTA DE FIGURAS ......................................................................................... 11 LISTA DE ANEXOS .......................................................................................... 12 RESUMEN ........................................................................................................ 13 ABSTRACT ...................................................................................................... 16 1. INTRODUCCION ....................................................................................... 19 2. PLANTEAMIENTO DEL PROBLEMA ......................................................... 21 3. JUSTIFICACIÓN ........................................................................................ 22 4. OBJETIVOS ............................................................................................... 23 4.1 Objetivo general ................................................................................... 23 4.2 Objetivos específicos ........................................................................... 23 5. MARCO TEÓRICO Y ESTADO DEL ARTE ................................................ 24 6. METODOLOGÍA......................................................................................... 40 6.1 Diseño: .................................................................................................... 40 6.2 Tiempo de Estudio: .................................................................................. 40 6.3 Población Blanco o diana: ....................................................................... 40 6.4 Selección de los pacientes ...................................................................... 40 6.6 Variables del estudio: .............................................................................. 41 6.9 Análisis de datos ..................................................................................... 42 7. CONSIDERACIONES ÉTICAS ................................................................... 43 8. RESULTADOS ........................................................................................... 44 8.1 ANÁLISIS UNIVARIADO...................................................................... 44 8.1.1 Características sociodemográficas de la población .......................... 44 8.1.2 Características clínicas de la población ............................................ 45 8.2 ANÁLISIS BIVARIADO ........................................................................ 56 8.2.1 Dependencia entre las variables sociodemográficas y la prevalencia de hipercolesterolemia familiar ...................................................................... 56 8.2.2 Dependencia entre las variables clínicas y la prevalencia de hipercolesterolemia familiar ........................................................................... 57 8 9. DISCUSIÓN ............................................................................................... 66 10. CONCLUSIONES ................................................................................... 71 11. LIMITACIONES ....................................................................................... 72 12. BIBLIOGRAFÍA ....................................................................................... 81spa
dc.format.mimetypeapplication/pdf
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titlePrevalencia de hipercolesterolemia familiar heterocigota en pacientes con enfermedad aterosclerótica establecida en dos instituciones de cuarto nivel del Nororiente Colombianospa
dc.title.translatedPrevalence of Heterozygous familial hypercholesterolemia in patients with atherosclerotic diseases in two level-IV institutions in a Northeast Colombianeng
dc.degree.nameEspecialista en Medicina Internaspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.rights.localAbierto (Texto Completo)spa
dc.publisher.facultyFacultad Ciencias de la Salud
dc.publisher.programEspecialización en Medicina Interna
dc.description.degreelevelEspecializaciónspa
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.localTesisspa
dc.type.coarhttp://purl.org/coar/resource_type/c_7a1f
dc.subject.keywordsInternal medicine
dc.subject.keywordsMedicine
dc.subject.keywordsHeterozygous familial hypercholesterolemia
dc.subject.keywordsPrevalence
dc.subject.keywordsCardiovascular disease
dc.subject.keywordsCardiological manifestations of general diseases
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga - UNAB
dc.identifier.reponamereponame:Repositorio Institucional UNAB
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2
dc.relation.referencesWorld Health Organization. Prevention of Cardiovascular Disease. Guidelines for assessment and management of cardiovascular risk. 2007.spa
dc.relation.referencesMinisterio de Salud y Protección Social. ASIS nacional Colombia 2013. Bogotá [sitio en Internet]; 2014. [Acceso 12 de mayo de 2015] Disponible en:https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-2015.pdfspa
dc.relation.referencesOrganización Panamericana de la Salud. Situación de salud en las américas. Indicadores básicos 2012.spa
dc.relation.referencesMúñoz O, García Á, Fernández D, Higuera A, Ruiz Á, Aschner P et al. Guía de práctica clínica para la prevención, detección temprana, diagnóstico, tratamiento y seguimiento de las dislipidemias: tratamiento farmacológico con estatinas. Revista Colombiana de Cardiología. 2015;22(1):14-21.spa
dc.relation.referencesAustin M. Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review. American Journal of Epidemiology. 2004;160(5):407-420.spa
dc.relation.referencesBenn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2012). Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. The Journal of Clinical Endocrinology & Metabolism, 97(11), 3956-3964.spa
dc.relation.referencesBesseling, J., Kindt, I., Hof, M., Kastelein, J. J., Hutten, B. A., & Hovingh, G. K. (2014). Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. Atherosclerosis, 233(1), 219-223.spa
dc.relation.referencesMerchán, A., Ruiz, Á. J., Campo, R., Prada, C. E., Toro, J. M., Sánchez, R., ... & Sixto, S. (2016). Hipercolesterolemia familiar: artículo de revisión. Revista colombiana de Cardiología, 23, 4-26.spa
dc.relation.referencesCiveira, F., & International Panel on Management of Familial Hypercholesterolemia. (2004). Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis, 173(1), 55-68.spa
dc.relation.referencesNordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., ... & Wiegman, A. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European heart journal, 34(45), 3478-3490.spa
dc.relation.referencesAuthors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., ... & Cifkova, R. (2012). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European heart journal, 33(13), 1635-1701.spa
dc.relation.referencesOPS. (2000). Situación de salud en las Américas: indicadores básicos 2016. OPS (Organización Panamericana de la Salud).spa
dc.relation.referencesLiu, K., Daviglus, M. L., Loria, C. M., Colangelo, L. A., Spring, B., Moller, A. C., & Lloyd-Jones, D. M. (2012). Healthy lifestyle through young adulthood and the presence of low cardiovascular disease risk profile in middle age: the Coronary Artery Risk Development in (Young) Adults (CARDIA) study. Circulation, 125(8), 996-1004.spa
dc.relation.referencesSantos, R. D., Gidding, S. S., Hegele, R. A., Cuchel, M. A., Barter, P. J., Watts, G. F., ... & Folco, E. (2016). Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. The lancet Diabetes & endocrinology, 4(10), 850-861.spa
dc.relation.referencesNordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., ... & Wiegman, A. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European heart journal, 34(45), 3478-3490.spa
dc.relation.referencesMata, P., Alonso, R., Ruiz, A., Gonzalez-Juanatey, J. R., Badimón, L., Díaz-Díaz, J. L., ... & Fuentes-Jiménez, F. (2015). Diagnóstico y tratamiento de la hipercolesterolemia familiar en España: documento de consenso. SEMERGEN-Medicina de Familia, 41(1), 24-33.spa
dc.relation.referencesMach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., ... & Graham, I. M. (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European heart journal, 41(1), 111-188.spa
dc.relation.referencesPisciotta, L., Fasano, T., Bellocchio, A., Bocchi, L., Sallo, R., Fresa, R., ... & Bertolini, S. (2007). Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients. Atherosclerosis, 194(2), e116-e122.spa
dc.relation.referencesAscaso, J. F., Mata, P., Arbona, C., Civeira, F., Valdivielso, P., & Masana, L. (2015). Hipercolesterolemia familiar homocigota: adaptación a España del documento de posición del grupo de consenso sobre hipercolesterolemia familiar de la Sociedad Europea de Arteriosclerosis. Documento de Consenso de la Sociedad Española de Arteriosclerosis (SEA) y la Fundación Hipercolesterolemia Familiar (FHF). Clínica e Investigación en Arteriosclerosis, 27(2), 80-96.spa
dc.relation.referencesJacobson, T. A., Ito, M. K., Maki, K. C., Orringer, C. E., Bays, H. E., Jones, P. H., ... & Wilson, D. P. (2015). National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. Journal of clinical lipidology, 9(2), 129-169.spa
dc.relation.referencesJacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., ... & Wild, R. A. (2015). National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. Journal of clinical lipidology, 9(6), S1-S122.spa
dc.relation.referencesMata, N., Alonso, R., Badimón, L., Padró, T., Fuentes, F., Muñiz, O., ... & Barba, A. (2011). Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART). Lipids in health and disease, 10(1), 94.spa
dc.relation.referencesParker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., ... & Thompson, P. D. (2013). Effect of statins on skeletal muscle function. Circulation, 127(1), 96-103.spa
dc.relation.referencesHeart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet, 360(9326), 7-22.spa
dc.relation.referencesKashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006). Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials. Circulation, 114(25), 2788–2797.spa
dc.relation.referencesRaal, F. J. (2013). Lomitapide for homozygous familial hypercholesterolaemia. The Lancet, 381(9860), 7-8.spa
dc.relation.referencesMalatack, MD, J. J. (2011). Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late. Pediatric transplantation, 15(2), 123-125.spa
dc.relation.referencesSjouke, B., Hovingh, G. K., Kastelein, J. J., & Stefanutti, C. (2015). Homozygous autosomal dominant hypercholesterolaemia: prevalence, diagnosis, and current and future treatment perspectives. Current opinion in lipidology, 26(3), 200-209.spa
dc.relation.referencesThompson, G. R., Catapano, A., Saheb, S., Atassi-Dumont, M., Barbir, M., Eriksson, M., ... & Parhofer, K. G. (2010). Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Current opinion in lipidology, 21(6), 492-498.spa
dc.relation.referencesBobrowska B, Zasada W, Rajtar-Salwa R, Dziewierz A, Dudek D. Prevalence of familial hypercholesterolemia in patients with acute coronary syndromes. Kardiol Pol. 2019: 475-7. 77.spa
dc.relation.referencesFaggiano, P., Pirillo, A., Griffo, R., Ambrosetti, M., Pedretti, R., Scorcu, G., ... & Sarullo, F. (2018). Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: the heredity survey. International journal of cardiology, 252, 193-198.spa
dc.relation.referencesRerup, S. A., Bang, L. E., Mogensen, U. M., Engstrøm, T., Jørgensen, E., Pedersen, F., ... & Køber, L. (2016). The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. American heart journal, 181, 35-42.spa
dc.relation.referencesLi, S., Zhang, Y., Zhu, C. G., Guo, Y. L., Wu, N. Q., Gao, Y., ... & Dong, Q. (2016). Identification of familial hypercholesterolemia in patients with myocardial infarction: a Chinese cohort study. Journal of clinical lipidology, 10(6), 1344-1352.spa
dc.relation.referencesNanchen, D., Gencer, B., Auer, R., Räber, L., Stefanini, G. G., Klingenberg, R., ... & Jüni, P. (2015). Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. European heart journal, 36(36), 2438-2445.spa
dc.relation.referencesKramer, A. I., Trinder, M., & Brunham, L. R. (2019). Estimating the prevalence of familial hypercholesterolemia in acute coronary syndrome: a systematic review and meta-analysis. Canadian Journal of Cardiology.spa
dc.relation.referencesPang, J., Poulter, E. B., Bell, D. A., Bates, T. R., Jefferson, V. L., Hillis, G. S., ... & Watts, G. F. (2015). Frequency of familial hypercholesterolemia in patients with early-onset coronary artery disease admitted to a coronary care unit. Journal of clinical lipidology, 9(5), 703-708.spa
dc.relation.referencesSawhney, J. P. S., Prasad, S. R., Sharma, M., Madan, K., Mohanty, A., Passey, R., ... & Mantri, R. R. (2019). Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India. Indian Heart Journal.spa
dc.relation.referencesPerez-Calahorra, S., Civeira, F., Guallar-Castillón, P., Pinto, X., Banegas, J. R., Pedro-Botet, J., ... & Laclaustra, M. (2020). Behavioural cardiovascular risk factors and prevalence of diabetes in subjects with familial hypercholesterolaemia. European Journal of Preventive Cardiologyspa
dc.relation.referencesNational Institute for Health and Clinical Excellence and The National Collaborating Centre for Primary Care, NICE Clinical Guideline 71. Identification and management of familial hypercholesterolaemia. http://www.nice.org.uk/guidance/CG071 (4 February 2015).spa
dc.relation.referencesHaralambos, K., Whatley, S. D., Edwards, R., Gingell, R., Townsend, D., Ashfield-Watt, P., ... & McDowell, I. F. W. (2015). Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales. Atherosclerosis, 240(1), 190-196.spa
dc.relation.referencesFaggiano, P., Pirillo, A., Griffo, R., Ambrosetti, M., Pedretti, R., Scorcu, G., ... & Sarullo, F. (2018). Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: the heredity survey. International journal of cardiology, 252, 193-198spa
dc.relation.referencesDe Luca, L., Arca, M., Temporelli, P. L., Colivicchi, F., Gonzini, L., Lucci, D., ... & Gulizia, M. M. (2018). Prevalence and pharmacologic management of familial hypercholesterolemia in an unselected contemporary cohort of patients with stable coronary artery disease. Clinical cardiology, 41(8), 1075-1083.spa
dc.relation.referencesZafrir, B., Jubran, A., Lavie, G., Halon, D. A., Flugelman, M. Y., & Shapira, C. (2017). Clinical features and gaps in the management of probable familial hypercholesterolemia and cardiovascular disease. Circulation Journal, 82(1), 218-223.spa
dc.relation.referencesRerup, S. A., Bang, L. E., Mogensen, U. M., Engstrøm, T., Jørgensen, E., Pedersen, F., ... & Køber, L. (2016). The prevalence and prognostic importance of possible familial hypercholesterolemia in patients with myocardial infarction. American heart journal, 181, 35-42.spa
dc.description.cvlachttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000070079spa
dc.description.cvlachttps://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000323578spa
dc.description.googlescholarhttps://scholar.google.es/citations?hl=es&user=-u8d7_QAAAAJspa
dc.identifier.orcidhttps://orcid.org/0000-0001-6258-1195
dc.identifier.orcidhttps://orcid.org/0000-0002-6233-9582
dc.description.scopushttps://www-scopus-com.aure.unab.edu.co/authid/detail.uri?authorId=6507727347spa
dc.description.scopushttps://www-scopus-com.aure.unab.edu.co/authid/detail.uri?authorId=16047325700spa
dc.description.researchgatehttps://www.researchgate.net/profile/Boris_Vesgaspa
dc.subject.lembMedicina internaspa
dc.subject.lembMedicinaspa
dc.subject.lembManifestaciones cardiológicas de enfermedades generalesspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.description.abstractenglishIntroduction: Heterozygous Familial Hypercholesterolemia is a genetic disorder characterized by elevation of c-LDL, usually over 190 mg/dl and high risk of cardiovascular morbidity and mortality. Despite its high social and economic impact, it remains an underdiagnosed and under-treated pathology. Design: An observational study, cross sectional analysis of anonymized secondary data. Methods: Inclusion criteria included: age 18 years or more, atherosclerotic cardiovascular disease (defined by patients with ischemic cardiomyopathy including myocardial infarction, angina, surgery or myocardial revascularization) and/or cerebrovascular disease (defined by cerebrovascular disease or transient ischemic attack. Exclusion criteria was the absent of lipid profile. Results: A total of 470 patients (males 63.83%) with an average age of 64.83 years old were included in this study. The findings of this study showed that hypertension (72.77%) was the most prevalent risk factor to develop cardiovascular events followed by dyslipidemia or being under hypolipidemic drug treatment (57.45%) and smoking (40.42%). Acute myocardial infarction (AMI) was the most frequent form of cardiovascular events (44.04%), followed by angina pectoris (45.53%) and ischemic cerebrovascular disease (CVD) (9.36%). 33.19% of cases had involvement of a single vessel in coronary arteriography, while 20.64% and 23.40% of cases had involvement of 2 and 3 or more vessels, respectively. The average value of LDL cholesterol (c-LDL) was 112.60 mg / dl and only 11.91% of the patients had values in the established goal for this condition. 43.96% of the population received some type of statin, but only 7.60% in maximum dose. Atorvastatin was the most prescribed statin (86.85%) after the cardiovascular event. 7.45% of the subjects were classified as possible cases of HFHe and 0.43% as probable cases. No definitive cases were found as there was no genetic analysis. It was established that 7.8% of the population studied has possible / probable HFHe. Statistically significant dependence (p &lt;0.0001) was determined between the HFHe and the age of presentation of earlier cardiovascular events (55.83 years old vs.65.60 years old), as well as with the female sex (p 0.021). Regarding the risk factors, only dependence was observed between having a history of HF in the first degree of consanguinity and family history of premature AMI with the prevalence of possible/probable HFHe (p &lt;0.0001). Patients with possible / probable HFHe had higher levels of CT (total cholesterol), GAD (triglycerides) and c-LDL (p &lt;0.0001). Dependency was found between the value of creatinine (0.82 mg / dl) and the prevalence of HFHe (p 0.005). Most patients with possible / probable HFHe perform another type of aerobic exercise other than walking (p 0.016). The combined treatment was prescribed 4 times more (10.81% vs. 2.54%) after the cardiovascular event in the possible / probable HF group (p 0.02). While coronary stent implantation was the most widely used revascularization strategy in general (63.19%), myocardial revascularization surgery was used 2 times more in the population with possible / probable HFHe (p 0.042). Conclusions: Heterozygous Familial Hypercholesterolemia (HFH) is an underdiagnosed disorder among patients who have established HFHe is an underdiagnosed disease among patients who have established atherosclerotic disease and shortens the age of presentation of cardiovascular events with respect to the general population. The results emphasise the importance of creating a cohort of patients with HFHe suffering from a cardiovascular event in order to optimize treatment measures, to reduce the impact of cardiovascular disease, and the costs related to care and treatment.spa
dc.subject.proposalHipercolesterolemia familiar heterocigotaspa
dc.subject.proposalEnfermedades cardiovascularesspa
dc.subject.proposalPrevalenciaspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by-nc-nd/2.5/co/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-nd/2.5/co/